Does Victoza lower blood pressure? Victoza (liraglutide) is a GLP-1 receptor agonist prescribed for type 2 diabetes mellitus in adults and children aged 10 years and above. Whilst its primary purpose is to improve blood glucose control, clinical evidence suggests it may produce modest reductions in systolic blood pressure—typically 1–3 mmHg—in some patients. This effect likely relates to associated weight loss and possible direct cardiovascular actions. However, Victoza is not licensed as an antihypertensive medication, and patients with hypertension require specific blood pressure treatments alongside diabetes management. Understanding how Victoza may influence blood pressure helps inform comprehensive cardiovascular risk management in type 2 diabetes.
Quick Answer: Victoza may produce modest reductions in systolic blood pressure of approximately 1–3 mmHg in some patients with type 2 diabetes, though it is not licensed or indicated as a blood pressure medication.
Victoza (liraglutide) is a prescription medicine used to treat type 2 diabetes mellitus in adults and children aged 10 years and above (paediatric use is specialist-led). It belongs to a class of medications called glucagon-like peptide-1 (GLP-1) receptor agonists. Victoza is administered once daily via subcutaneous injection, typically in the abdomen, thigh, or upper arm, independent of meals.
The primary mechanism of action involves mimicking the effects of GLP-1, a naturally occurring hormone in the body. When blood glucose levels rise after eating, Victoza stimulates the pancreas to release insulin whilst simultaneously suppressing the release of glucagon, a hormone that raises blood sugar. This dual action helps to regulate blood glucose levels more effectively. Additionally, Victoza slows gastric emptying, which means food moves more slowly from the stomach into the small intestine, contributing to improved post-meal glucose control and increased feelings of fullness.
Victoza is typically prescribed when diet and exercise alone, or other diabetes medications such as metformin, have not provided adequate glycaemic control. According to NICE guidance (NG28), GLP-1 receptor agonists like Victoza are usually considered as part of triple therapy regimens for type 2 diabetes management, typically when BMI is ≥35 kg/m² (adjusted for ethnicity), where insulin would be unacceptable, or when weight loss would benefit obesity-related comorbidities. The medication has also been associated with weight loss in many patients, which can be beneficial given the strong link between obesity and type 2 diabetes.
Common side effects include nausea, diarrhoea, vomiting, and constipation, particularly when starting treatment. These gastrointestinal symptoms often improve over time as the body adjusts to the medication. More serious but less common adverse effects include pancreatitis and gallbladder disease. There is also a risk of dehydration from gastrointestinal side effects, which can affect blood pressure. When used with insulin or sulfonylureas, Victoza may increase the risk of hypoglycaemia. Victoza is not indicated for type 1 diabetes or diabetic ketoacidosis.
The starting dose is typically 0.6 mg once daily, which is increased after at least one week to 1.2 mg, and if needed to a maximum of 1.8 mg daily.
Mounjaro® is the most innovative GLP-1 medication proven to dramatically curb appetite, hunger, and cravings to help professional men achieve substantial weight loss.
Start Here
Wegovy® is a weekly injectable GLP-1 medication with proven effectiveness in reducing appetite, hunger, and cravings to help busy professionals lose significant weight.
Start HereResearch evidence suggests that Victoza may have a modest blood pressure-lowering effect in some patients with type 2 diabetes, though this is not its primary therapeutic purpose. Clinical trials have demonstrated small but statistically significant reductions in systolic blood pressure (the top number in a blood pressure reading) among patients taking liraglutide.
The mechanism behind this potential blood pressure reduction is not entirely understood, but several factors may contribute. Weight loss associated with Victoza use is likely a significant contributor, as reducing body weight typically leads to improvements in blood pressure. Additionally, GLP-1 receptor agonists may have direct effects on the cardiovascular system, including potentially promoting sodium excretion by the kidneys (natriuresis) and possibly improving endothelial function—the health of blood vessel linings. However, these mechanisms beyond weight loss remain hypothetical and require further research confirmation.
In the landmark LEADER trial (New England Journal of Medicine, 2016), which examined cardiovascular outcomes in patients with type 2 diabetes and high cardiovascular risk, participants taking liraglutide experienced an average reduction in systolic blood pressure of approximately 1-3 mmHg compared to placebo. Whilst this reduction is modest, it may contribute to overall cardiovascular risk reduction when combined with other beneficial effects of the medication.
It is crucial to understand that Victoza is not licensed or indicated as a blood pressure medication. Patients with hypertension should not rely on Victoza alone for blood pressure management. If you have both diabetes and high blood pressure, your GP will typically prescribe specific antihypertensive medications such as ACE inhibitors, calcium channel blockers, or thiazide-like diuretics alongside your diabetes treatment. The potential blood pressure benefits of Victoza should be viewed as a possible additional advantage rather than a primary treatment effect.
Regular blood pressure monitoring is an essential component of diabetes care, regardless of whether you are taking Victoza. The NHS recommends that people with type 2 diabetes have their blood pressure checked at least annually, and more frequently if readings are elevated or if you are taking blood pressure medications.
Home blood pressure monitoring can provide valuable information about your cardiovascular health. If you choose to monitor your blood pressure at home, ensure you:
Use a validated, properly calibrated blood pressure monitor (preferably an upper-arm device rather than a wrist monitor) from the British and Irish Hypertension Society validated device list
Take readings at consistent times of day, ideally in the morning and evening
Sit quietly for five minutes before taking a measurement
Record your readings in a diary or app to share with your healthcare team
Take multiple readings (at least two) and calculate the average
When starting Victoza, your GP or diabetes nurse may recommend more frequent blood pressure checks during the initial months of treatment. This allows your healthcare team to monitor for any changes and adjust other medications if necessary. Some patients taking multiple medications for diabetes and hypertension may require dose adjustments to their blood pressure tablets if significant changes occur.
According to NICE guidance, the target blood pressure for most adults with diabetes is typically below 140/90 mmHg in clinic measurements (or below 135/85 mmHg for home measurements). Lower targets (below 130/80 mmHg in clinic) may be appropriate for those with kidney disease, retinopathy, or certain types of target-organ damage. Your GP will discuss your specific blood pressure goals with you. Keep in mind that blood pressure naturally fluctuates throughout the day, so a single elevated reading does not necessarily indicate a problem. Consistent patterns of elevated readings warrant discussion with your healthcare provider.
If hypertension is suspected, your doctor may recommend confirmation with ambulatory (ABPM) or home blood pressure monitoring (HBPM) before making treatment decisions.
You should contact your GP or diabetes care team if you experience significant changes in blood pressure after starting Victoza, whether increases or decreases. Whilst modest reductions may be beneficial, substantial drops in blood pressure could cause symptoms such as dizziness, light-headedness, or fainting, particularly when standing up quickly (postural hypotension).
Seek medical advice if you experience:
Persistent dizziness or feeling faint, especially upon standing
Unusually low blood pressure readings (systolic below 90 mmHg)
Consistently elevated blood pressure readings above your target range
Symptoms of low blood pressure, including weakness, confusion, or blurred vision
Any concerns about interactions between Victoza and your blood pressure medications
Seek urgent same-day medical attention if:
Your blood pressure is ≥180/120 mmHg, even without symptoms
You have severe, persistent abdominal pain (with or without vomiting), which could indicate pancreatitis
You experience chest pain, severe breathlessness, new confusion, or focal neurological symptoms
You cannot maintain adequate hydration due to vomiting or diarrhoea
If you are taking blood pressure medications alongside Victoza and experience symptoms of low blood pressure, do not stop taking any prescribed medications without consulting your GP first. Your doctor may need to adjust the doses of your antihypertensive medications to account for any blood pressure changes associated with Victoza and weight loss.
Dehydration from gastrointestinal side effects of Victoza (vomiting, diarrhoea) can lower blood pressure. Ensure adequate fluid intake, especially if experiencing these side effects, and seek medical advice if unable to maintain hydration.
Regular diabetes review appointments provide an opportunity to discuss how Victoza is working for you, including any effects on blood pressure, weight, and overall diabetes control. Your GP can assess whether your current treatment regimen remains appropriate or whether adjustments are needed. Remember that managing type 2 diabetes and associated cardiovascular risk factors is a collaborative process between you and your healthcare team, requiring ongoing monitoring and communication.
If you suspect any side effects from Victoza, report them to your healthcare professional or directly to the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk or via the Yellow Card app).
No, Victoza is not licensed or indicated as a blood pressure medication. Whilst it may produce modest blood pressure reductions of 1–3 mmHg in some patients, those with hypertension require specific antihypertensive medications prescribed by their GP alongside diabetes treatment.
The blood pressure-lowering effect likely results from weight loss associated with Victoza use, as reducing body weight typically improves blood pressure. Additionally, GLP-1 receptor agonists may promote sodium excretion by the kidneys and possibly improve endothelial function, though these mechanisms require further research confirmation.
According to NICE guidance, the target blood pressure for most adults with diabetes is typically below 140/90 mmHg in clinic measurements or below 135/85 mmHg for home measurements. Lower targets (below 130/80 mmHg in clinic) may be appropriate for those with kidney disease, retinopathy, or certain types of target-organ damage.
All medical content on this blog is created based on reputable, evidence-based sources and reviewed regularly for accuracy and relevance. While we strive to keep content up to date with the latest research and clinical guidelines, it is intended for general informational purposes only.
DisclaimerThis content is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional with any medical questions or concerns. Use of the information is at your own risk, and we are not responsible for any consequences resulting from its use.
